A groundbreaking study offers a glimmer of hope for women struggling with the debilitating symptoms of menopause, particularly hot flashes and night sweats. But here's where it gets controversial: the research suggests that a woman's insulin levels in midlife could be a key factor in determining the timing and duration of these symptoms.
The study, led by Faria Athar and published in The Journal of Clinical Endocrinology & Metabolism, found that higher insulin levels at age 47 predicted an earlier onset and longer duration of hot flashes and night sweats. Athar, a UVic PhD graduate, explains that these findings help fill gaps in our understanding of menopause symptoms and their varying severity among women.
Vasomotor symptoms, including hot flashes, night sweats, and cold sweats, affect a staggering 75% of women during the menopausal transition. These symptoms can appear years before a woman's final menstrual period and persist for up to a decade afterward, significantly impacting their quality of life.
Imagine trying to maintain your composure during a board meeting while suddenly feeling feverish and flushed, or struggling to care for your family and perform your job effectively when sleep is disrupted by night sweats. These symptoms are not experienced equally by all women, with variations in age of onset, severity, and duration.
Prior research has shown that factors such as race, ethnicity, and socioeconomic status play a role. For example, more Black women report symptoms than women of Asian descent, and the severity of symptoms can vary within the same ethnic group depending on their location and socioeconomic status.
The link between menopause and metabolic health is becoming increasingly clear. Nicole Templeman, assistant professor of biology at UVic and Tier 2 Canada Research Chair in Metabolic Determinants of Reproduction and Aging, explains that there is growing awareness of the interplay between metabolic and reproductive health.
Women with higher body fat percentages and insulin resistance report more frequent and severe vasomotor symptoms, particularly early in the menopausal transition. Additionally, increased symptom severity has been associated with a higher risk of developing type 2 diabetes.
Templeman and her team decided to investigate whether insulin levels prior to menopause could provide insights into the incidence and severity of menopause symptoms. Their study utilized data from the Study of Women's Health Across the Nation (SWAN), which followed women from a pre-/perimenopausal baseline (aged 42-52) over 10 years across seven sites in the US.
The researchers found that insulin levels and body mass index (BMI) at age 47 were both predictors of vasomotor symptom timing and duration. Higher insulin or BMI corresponded with an earlier onset of hot flashes. Interestingly, insulin may be a stronger predictor of hot flashes when considering other metabolic variables, while BMI appeared more closely associated with estrogen level changes.
These findings raise the possibility of effective lifestyle interventions to manage vasomotor symptoms. While reversing obesity is complex, insulin levels may be more responsive to lifestyle changes. Exercise training, for instance, can lower insulin levels even without weight loss.
This study indicates that the metabolic health of women in their 40s, including insulin levels, could influence their experience of the menopausal transition. Further investigation is warranted to explore these possibilities and provide women with effective strategies to manage their symptoms.
The Templeman Lab's research aligns with the United Nations Sustainable Development Goal 3, promoting good health and well-being. Learn more about their work and the SDGs at UVic.
